Table 1.
Surface markers | Ctr | LPS | 7oxo-C | Resveratrol | Resveratrol + 7oxo-C | P value | |
---|---|---|---|---|---|---|---|
M1 | |||||||
CD14 | % | 98.6 ± 1.1 | 100.0 ± 0.0 | 98.0 ± 3.5 | 99.3 ± 1.1 | 98.6 ± 1.1 | NS |
MFI | 1810.0 ± 569.1 | 3107.0 ± 1128.0 | 2457.0 ± 737.8 | 1743.0 ± 568.1 | 1837.0 ± 304.8 | NS | |
CD16 | % | 30.7 ± 14.0 | 39.0 ± 6.0 | 35.0 ± 7.0 | 25.0 ± 15.0 | 22.7 ± 12.0 | NS |
MFI | 1001.0 ± 107.5∗† | 625.0 ± 52.0* | 472.0 ± 148.0†‡ | 809.3 ± 121.1 | 977.0 ± 98.3‡ |
∗‡<0.05 †<0.001 |
|
CD163 | % | 8.3 ± 0.6 | 35.7 ± 23.0 | 15.7 ± 5.8 | 8.7 ± 0.6 | 8.6 ± 0.6 | NS |
MFI | 1113 ± 554.1 | 1046.0 ± 461.4 | 999.7 ± 650.9 | 1061.0 ± 191.0 | 1015.0 ± 179.7 | NS | |
HLA-DR | % | 99.7 ± 0.6 | 98.3 ± 2.0 | 99.3 ± 0.6 | 99.3 ± 0.6 | 99.3 ± 0.6 | NS |
MFI | 1343.0 ± 239.8∗† | 5296.0 ± 1264.0 | 5601.0 ± 777.8* | 1632.0 ± 178.1 | 5883.0 ± 2427.0† | <0.05 | |
| |||||||
M2 | |||||||
CD14 | % | 93.3 ± 9.9 | 99.3 ± 1.1 | 98.0 ± 3.5 | 99.3 ± 1.1 | 99.3 ± 1.1 | NS |
MFI | 2103.0 ± 149.8∗† | 7277.0 ± 2699.0* | 8199.0 ± 1501.0†‡§ | 2103.0 ± 952.6‡ | 2424.0 ± 479.8§ | <0.001 | |
CD16 | % | 43.0 ± 17.1 | 39.3 ± 16.0 | 35.3 ± 2.5 | 25.0 ± 8.0 | 27.0 ± 5.6 | NS |
MFI | 434.0 ± 86.1 | 421.7 ± 137.6 | 448.3 ± 159.9 | 402.0 ± 71.2 | 445.3 ± 115.8 | NS | |
CD163 | % | 92.7 ± 11.9 | 96.3 ± 5.5 | 93.3 ± 10.7 | 93.7 ± 8.5 | 94.0 ± 10.4 | NS |
MFI | 1663.0 ± 409.5 | 1058.0 ± 208.8 | 1083.0 ± 195.6 | 1685.0 ± 223.1 | 1416.0 ± 480.0 | NS | |
HLA-DR | % | 99.0 ± 0.0 | 98.7 ± 0.6 | 99.3 ± 0.6 | 100.0 ± 0.0 | 99.3 ± 0.6 | NS |
MFI | 3143.0 ± 1630.0 | 3019.0 ± 994.5 | 4247.0 ± 947.0 | 4636.0 ± 1235.0 | 4718.0 ± 1747 | NS |
Results are expressed as percentage of positive cells (%) and mean fluorescence intensity (MFI) (mean ± SD; n = 3). P values were calculated by one-way ANOVA with a Bonferroni post hoc test. 7oxo-C: 7-oxo-cholesterol; NS: no significance. CD16 MFI: ctr M1 versus ctr M2, P < 0.001; CD163 %: ctr M1 versus ctr M2, P < 0.05.
∗†§‡: indicate the statistical significant difference between numbers with the same symbol.